![Nils Bergenhem](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Nils Bergenhem
Direttore Tecnico/Scientifico/R&S presso Egenix, Inc.
Profilo
Nils Bergenhem is currently the Chief Scientific Officer at Egenix, Inc. He previously held positions as the Director-Diabetes Research at OSI Pharmaceuticals, Inc., Chief Scientific Officer at AdipoGenix, Inc., Chief Scientific Officer at CPEX Pharmaceuticals, Inc., Chief Scientific Officer at Escoublac, Inc., Scientific Manager at Mitsubishi Tanabe Pharma Corp., Research Investigator at the University of Michigan, and Principal at Novo Nordisk, Inc. He also served as the Vice President-Research at The Institute for Diabetes Discovery.
Dr. Bergenhem obtained his graduate degree from the University of Michigan, his undergraduate degree from the University of Linköping, and his doctorate from Umea Universitet.
Posizioni attive di Nils Bergenhem
Società | Posizione | Inizio |
---|---|---|
Egenix, Inc.
![]() Egenix, Inc. BiotechnologyHealth Technology Part of Denan, Inc., Egenix, Inc. engages in cancer therapeutics research and development. The company is based in Millbrook, NY. Egenix was acquired by Denan, Inc. on June 10, 2015 for $0.82 million. | Direttore Tecnico/Scientifico/R&S | 25/07/2011 |
Precedenti posizioni note di Nils Bergenhem
Società | Posizione | Fine |
---|---|---|
Escoublac, Inc.
![]() Escoublac, Inc. BiotechnologyHealth Technology Escoublac, Inc. offers treatment for obesity and related disorders. It aims to transform the discovery into new therapies for metabolic disorders and related conditions such as obesity and type II diabetes. The company was founded in 2007 by Gerard Karsenty and is headquartered in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | 01/01/2010 |
AdipoGenix, Inc.
![]() AdipoGenix, Inc. Pharmaceuticals: MajorHealth Technology AdipoGenix, Inc. develops molecular pharmaceutical products. It offers small molecule pharmaceuticals to treat obesity and its co-morbidities. The firm’s technology includes AdipoBASE, AdipoSCREEN, AdipoPATH and AdipoTARGET. The company was founded by Gerri Waloga, Barbara E. Corkey, Stephen R. Farmer, James A. Hamilton, James L. Kirkland, H. Jeff Leighton and Paul F. Pilch in 1997 and is headquartered in Boston, MA. | Direttore Tecnico/Scientifico/R&S | 01/12/2007 |
The Institute for Diabetes Discovery
![]() The Institute for Diabetes Discovery Medical/Nursing ServicesHealth Services Part of The Institutes for Pharmaceutical Discovery, Inc., The Institute for Diabetes Discovery provides diabetes health care services. | Direttore Tecnico/Scientifico/R&S | 01/01/2005 |
OSI PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2002 |
University of Michigan | Corporate Officer/Principal | - |
Formazione di Nils Bergenhem
University of Michigan | Graduate Degree |
University of Linköping | Undergraduate Degree |
Umea Universitet | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 8 |
---|---|
OSI Pharmaceuticals, Inc.
![]() OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
AdipoGenix, Inc.
![]() AdipoGenix, Inc. Pharmaceuticals: MajorHealth Technology AdipoGenix, Inc. develops molecular pharmaceutical products. It offers small molecule pharmaceuticals to treat obesity and its co-morbidities. The firm’s technology includes AdipoBASE, AdipoSCREEN, AdipoPATH and AdipoTARGET. The company was founded by Gerri Waloga, Barbara E. Corkey, Stephen R. Farmer, James A. Hamilton, James L. Kirkland, H. Jeff Leighton and Paul F. Pilch in 1997 and is headquartered in Boston, MA. | Health Technology |
CPEX Pharmaceuticals, Inc.
![]() CPEX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology CPEX Pharmaceuticals, Inc. is engaged in the development, licensing and commercialization of pharmaceutical products utilizing its validated drug delivery technology. Its technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through formulation development with proprietary molecules such as CPE-215. The company's first product is Testim, a gel for testosterone replacement therapy, which is a formulation of its technology with testosterone. Testim is licensed to Auxilium Pharmaceuticals, Inc., which is currently marketing it in the United States, Europe and other countries. Its other product is Nasulin, which is an intranasal formulation of insulin being developed to treat hyperglycemia in patients suffering from Type 1 and Type 2 diabetes. The company was founded on September 28, 2007 and is headquartered in Exeter, NH. | Health Technology |
Escoublac, Inc.
![]() Escoublac, Inc. BiotechnologyHealth Technology Escoublac, Inc. offers treatment for obesity and related disorders. It aims to transform the discovery into new therapies for metabolic disorders and related conditions such as obesity and type II diabetes. The company was founded in 2007 by Gerard Karsenty and is headquartered in Cambridge, MA. | Health Technology |
Mitsubishi Tanabe Pharma Corp.
![]() Mitsubishi Tanabe Pharma Corp. Pharmaceuticals: OtherHealth Technology Mitsubishi Tanabe Pharma Corp. engages in the research, development, manufacture, and sale of pharmaceutical products. Its products include Remicade, Ceredist, Talion, Kremezin, Maintate, Simponi, Lexapro, Tenelia, Tetrabik, and Imusera. The company was founded by Gohei Tanabeya in 1678 and is headquartered in Osaka, Japan. | Health Technology |
Novo Nordisk, Inc.
![]() Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |
The Institute for Diabetes Discovery
![]() The Institute for Diabetes Discovery Medical/Nursing ServicesHealth Services Part of The Institutes for Pharmaceutical Discovery, Inc., The Institute for Diabetes Discovery provides diabetes health care services. | Health Services |
Egenix, Inc.
![]() Egenix, Inc. BiotechnologyHealth Technology Part of Denan, Inc., Egenix, Inc. engages in cancer therapeutics research and development. The company is based in Millbrook, NY. Egenix was acquired by Denan, Inc. on June 10, 2015 for $0.82 million. | Health Technology |
- Borsa valori
- Insiders
- Nils Bergenhem